ACTIVE

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result432,3 k €+49,2 %over 1 year

Revenue10,4 M €+4,3 %over 1 year

Equity6,7 M €+6,9 %over 1 year

Workforce28,6 ETP+8,7 %over 1 year

Identity

Source · BCE/KBO

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE is a Non-profit organization incorporated in 1966. Its main activity is: Other professional, scientific and technical activities. Its registered office is in Bruxelles. It employs on average 28,6 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0407.622.902
Incorporation: 26/10/1966
Legal form: Non-profit organization
Registered office: Cantersteen 47
1000 Bruxelles · BruxellesSee on map
Latest accounts: 31/12/2025
Average workforce: 28,6 ETP

Activities (NACE)

74879Other professional, scientific and technical activities· main 82990Other business support service activities n.e.c.82990Other business support service activities n.e.c.91110Libraries, archives, museums and other cultural activities 94110Activities of business and employers membership organisations 94110Activities of business and employers membership organisations

Joint committees (2)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 20 filings

Trend over 19 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	10,4 M €	+4.3%	9,9 M €	+1.8%	9,8 M €	+11.1%	8,8 M €	+16.1%	7,6 M €
EBITDA	443 k €	+51.5%	292,5 k €	-58.2%	699,8 k €	-25.9%	943,9 k €	-26.0%	1,3 M €
Operating result	262 k €	+36.3%	192,2 k €	-68.6%	611,9 k €	-25.8%	824,7 k €	-28.3%	1,2 M €
Net result	432,3 k €	+49.2%	289,6 k €	-63.3%	788,8 k €	+43.8%	548,6 k €	-52.4%	1,2 M €
Balance sheet
Equity	6,7 M €	+6.9%	6,3 M €	+4.8%	6 M €	+15.1%	5,2 M €	+11.8%	4,7 M €
Total assets	9,3 M €	+8.9%	8,5 M €	+5.8%	8 M €	+21.9%	6,6 M €	+21.9%	5,4 M €
Cash	4,8 M €	+38.0%	3,5 M €	-14.6%	4,1 M €	+25.3%	3,2 M €	+25.3%	2,6 M €
Debts	1,7 M €	+1.2%	1,7 M €	+8.2%	1,6 M €	+22.0%	1,3 M €	+81.5%	718 k €
Other
Workforce	28,6 ETP	+8.7%	26,3 ETP	+5.6%	24,9 ETP	+2.0%	24,4 ETP	-5.1%	25,7 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

12 active · 22 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Almirall0403.090.131Represented by Gregory Paton	Director11/06/2025 → 07/06/2028
AMGEN0439.652.401Represented by Sara Schaufelberger	Director23/03/2012 → 07/06/2028Mandateended
MSD BELGIUM0406.820.770Represented by Katrien De Vos	Director18/03/2016 → 07/06/2028Vice-chairman of the board of directors22/03/2013 → 22/03/2019endedMandateended
ROCHE0403.088.151Represented by Marie-José Borst	Director25/03/2011 → 07/06/2028Mandateended
S.A. NOVO NORDISK PHARMA N.V.0414.695.586Represented by Axel De Muyt	Director11/06/2025 → 07/06/2028
TAKEDA BELGIUM0403.054.202Represented by Bruno Rabilier	Director17/03/2021 → 07/06/2028
UCB PHARMA0403.096.168Represented by Xavier Hormaechea	Vice-chairman of the board of directors23/03/2022 → 07/06/2028Director22/03/2013 → 26/03/2025endedMandateended
ABBVIE0845.096.860Represented by Renaud Decroix	Director23/03/2012 → 09/06/2027Vice-chairman of the board of directorsended
Bayer0404.754.571Represented by Niels Hessmann	Director13/03/2024 → 09/06/2027
Eli Lilly Benelux0406.754.454Represented by Frédéric Clais	Chairman of the board of directors17/03/2021 → 09/06/2027Vice-chairman of the board of directors23/03/2018 → 20/03/2024endedDirector23/03/2012 → 26/03/2021endedMandateended
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline0403.066.474Represented by Emmanuelle Boishardy	Director28/03/2014 → 09/06/2027Mandateended
Pfizer0401.994.823Represented by David Lepoittevin	Director23/03/2012 → 09/06/2027Vice-chairman of the board of directors17/03/2021 → 20/03/2024endedChairman of the board of directors23/03/2018 → 20/03/2024endedMandateended

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
AstraZeneca0400.165.679Represented by Keira Driansky	Director22/03/2023 → 10/06/2026
BRISTOL - MYERS SQUIBB BELGIUM0403.075.184Represented by Sally McNab	Director22/03/2023 → 18/03/2026

Other companies at this address

Cantersteen 47 1000 Bruxelles

Company	CBE no.
13 ANALYTICS● Active	0793.625.987
AA Investissements● Active	0506.804.115
ACTUA Formation Benelux● Active	0778.940.781
Administratiekantoor Superlinear● Active	1034.146.494
Agilite Solutions Belgium● Active	1007.736.067
AGUILA INTERNATIONAL RISK● Active	1010.584.897
Ahead Digital● Active	0867.212.266
AlexandriteF● Active	0804.051.905
Alexandrite Monnet Belgian Bidco● Active	0780.685.989
ALTHERIA SOLUTIONS● Active	0696.869.477
AMBOS Law● Active	0550.946.241
AMCAHub● Active	1025.495.282
AMICALE DES ANCIENS DE LA SHELL - VRIENDENKRING VAN DE OUDGEDIENDEN VAN DE SHELL● Active	0409.404.336
Ampyr Distributed Energy Belgium 1● Active	0800.049.664
Ampyr Distributed Energy Belgium 2● Active	0742.927.255
ARCORA INGEROP BELGIUM● Active	0733.604.961
Aricoma Systems● Active	0767.591.979
Arts 28● Active	1025.504.487
A & S PRODUCTIONS● Active	0453.963.760
ATowerHub● Active	1025.504.388

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	16/06/2026	17/06/2025	29/03/2024	24/04/2023	05/04/2022	23/03/2021
General meeting	03/06/2026	11/06/2025	13/03/2024	22/03/2023	23/03/2022	17/03/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 20 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	03/06/2026	16/06/2026	Dutch	PDF
Full model	31/12/2024	11/06/2025	17/06/2025	Dutch	PDF
Full model	31/12/2023	13/03/2024	29/03/2024	Dutch	PDF
Full model	31/12/2022	22/03/2023	24/04/2023	Dutch	PDF
Full model	31/12/2021	23/03/2022	05/04/2022	Dutch	PDF
Full model	31/12/2020	17/03/2021	23/03/2021	Dutch	PDF
Full model	31/12/2019	13/05/2020	08/06/2020	Dutch	PDF
Full model	31/12/2018	27/03/2019	15/04/2019	Dutch	PDF
Full model	31/12/2017	23/03/2018	27/03/2018	Dutch	PDF
Full model	31/12/2016	24/03/2017	10/04/2017	Dutch	PDF
Full model	31/12/2015	18/03/2016	24/03/2016	Dutch	PDF
Full model	31/12/2014	27/03/2015	23/04/2015	Dutch	PDF
Full model	31/12/2013	28/03/2014	14/04/2014	Dutch	PDF
Full model	31/12/2012	22/03/2013	29/11/2013	Dutch	PDF
Full model	31/12/2011	23/03/2012	29/11/2013	Dutch	PDF
Full model	31/12/2010	26/03/2011	29/12/2011	Dutch	PDF
Full model	31/12/2009	26/03/2010	22/12/2011	Dutch	PDF
Full model	31/12/2008	27/03/2009	31/08/2009	Dutch	PDF
Full model	31/12/2007	21/03/2008	21/09/2009	Dutch	PDF
Full model	31/12/2006	30/03/2007	06/12/2007	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

12 active · 22 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Almirall0403.090.131Represented by Gregory Paton	Director11/06/2025 → 07/06/2028
AMGEN0439.652.401Represented by Sara Schaufelberger	Director23/03/2012 → 07/06/2028Mandateended
MSD BELGIUM0406.820.770Represented by Katrien De Vos	Director18/03/2016 → 07/06/2028Vice-chairman of the board of directors22/03/2013 → 22/03/2019endedMandateended
ROCHE0403.088.151Represented by Marie-José Borst	Director25/03/2011 → 07/06/2028Mandateended
S.A. NOVO NORDISK PHARMA N.V.0414.695.586Represented by Axel De Muyt	Director11/06/2025 → 07/06/2028
TAKEDA BELGIUM0403.054.202Represented by Bruno Rabilier	Director17/03/2021 → 07/06/2028
UCB PHARMA0403.096.168Represented by Xavier Hormaechea	Vice-chairman of the board of directors23/03/2022 → 07/06/2028Director22/03/2013 → 26/03/2025endedMandateended
ABBVIE0845.096.860Represented by Renaud Decroix	Director23/03/2012 → 09/06/2027Vice-chairman of the board of directorsended
Bayer0404.754.571Represented by Niels Hessmann	Director13/03/2024 → 09/06/2027
Eli Lilly Benelux0406.754.454Represented by Frédéric Clais	Chairman of the board of directors17/03/2021 → 09/06/2027Vice-chairman of the board of directors23/03/2018 → 20/03/2024endedDirector23/03/2012 → 26/03/2021endedMandateended
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline0403.066.474Represented by Emmanuelle Boishardy	Director28/03/2014 → 09/06/2027Mandateended
Pfizer0401.994.823Represented by David Lepoittevin	Director23/03/2012 → 09/06/2027Vice-chairman of the board of directors17/03/2021 → 20/03/2024endedChairman of the board of directors23/03/2018 → 20/03/2024endedMandateended

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
AstraZeneca0400.165.679Represented by Keira Driansky	Director22/03/2023 → 10/06/2026
BRISTOL - MYERS SQUIBB BELGIUM0403.075.184Represented by Sally McNab	Director22/03/2023 → 18/03/2026

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates27/01/2026
ONTSLAGEN - BENOEMINGEN
PDF
Mandates27/01/2026
ONTSLAGEN - BENOEMINGEN
PDF
Mandates17/11/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates17/11/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates22/07/2025
DEMISSIONS, NOMINATIONS - ASSEMBLEE GENERALE
PDF
Mandates22/07/2025
ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
PDF
Mandates04/04/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates04/04/2025
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings19 filings

Mandates

TAKEDA BELGIUM

ROCHE

Almirall

UCB PHARMA

MSD BELGIUM

S.A. NOVO NORDISK PHARMA N.V.

AMGEN

Pfizer

GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline

Bayer

Eli Lilly Benelux

ABBVIE

and 16 more mandates

196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Cantersteen 47, 1000 BrusselsTerhulpsesteenweg 166, 1170 Watermael-Boitsfort

Director

Vice-chairman of the board of directorsDirector

DirectorVice-chairman of the board of directors

Director

DirectorVice-chairman of the board of directorsChairman of the board of directors

Director

Chairman of the board of directorsVice-chairman of the board of directorsDirector

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Cantersteen 47, 1000 BrusselsCurrent	accounts 2024 → 2025	Accounts 2025 · 2026-00170309
Terhulpsesteenweg 166, 1170 Watermael-Boitsfort	accounts 2021 → 2023	Accounts 2023 · 2024-00054894

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIECurrent	accounts 2007 → 2025	Accounts 2025 · 2026-00170309

Events

2025
Annual accounts 2025432,3 k €↑
2024
Annual accounts 2024289,6 k €↓
2023
Annual accounts 2023788,8 k €↑
2022
Annual accounts 2022548,6 k €↓
2021
Annual accounts 20211,2 M €↑
2020
Annual accounts 2020381,5 k €↑
2019
Annual accounts 201922,7 k €↑
2018
Annual accounts 201811,9 k €↑
2017
Annual accounts 2017-43,7 k €↓
2016
Annual accounts 2016657,2 k €↑
2015
Annual accounts 2015428,2 k €↑
2014
Annual accounts 2014-239,8 k €↑
2013
Annual accounts 2013-1,7 M €↓
2012
Annual accounts 2012-426 k €↓
2011
Annual accounts 201127,3 k €↓
2010
Annual accounts 2010428,9 k €↓
2009
Annual accounts 2009607,1 k €↑
2008
Annual accounts 2008211,1 k €↑
2007
Annual accounts 2007198,6 k €
26/10/1966
IncorporationNon-profit organization

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events